B L Hazleman

3.2k total citations
52 papers, 2.3k citations indexed

About

B L Hazleman is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B L Hazleman has authored 52 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Rheumatology, 15 papers in Radiology, Nuclear Medicine and Imaging and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B L Hazleman's work include Systemic Lupus Erythematosus Research (17 papers), Vasculitis and related conditions (13 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). B L Hazleman is often cited by papers focused on Systemic Lupus Erythematosus Research (17 papers), Vasculitis and related conditions (13 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). B L Hazleman collaborates with scholars based in United Kingdom, France and China. B L Hazleman's co-authors include Allan Binder, Jeremy G. Jones, V Kyle, Mary T. Keogan, Herman Waldmann, G Hale, A G Mowat, John D. Isaacs, Stephen Cobbold and Richard A. Watts and has published in prestigious journals such as The Lancet, Gut and Annals of the Rheumatic Diseases.

In The Last Decade

B L Hazleman

51 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B L Hazleman United Kingdom 23 896 680 413 410 406 52 2.3k
Francesco Trotta Italy 36 1.9k 2.1× 343 0.5× 207 0.5× 150 0.4× 535 1.3× 154 3.6k
Gurtej S. Cheema United States 24 1.3k 1.5× 241 0.4× 161 0.4× 172 0.4× 266 0.7× 26 2.9k
Conny J. van der Laken Netherlands 32 1.4k 1.5× 318 0.5× 161 0.4× 138 0.3× 424 1.0× 100 2.8k
C Nagant de Deuxchaisnes Belgium 21 801 0.9× 168 0.2× 517 1.3× 85 0.2× 313 0.8× 79 2.3k
H. Roels Belgium 27 534 0.6× 569 0.8× 77 0.2× 66 0.2× 434 1.1× 111 2.3k
Philippe Dieudé France 37 1.8k 2.0× 946 1.4× 90 0.2× 237 0.6× 429 1.1× 190 4.1k
Christina Duftner Austria 26 1.5k 1.7× 1.2k 1.8× 80 0.2× 351 0.9× 254 0.6× 84 3.0k
Peter Youssef Australia 29 1.3k 1.4× 817 1.2× 100 0.2× 91 0.2× 331 0.8× 87 3.0k
Alfred J. Fish United States 26 313 0.3× 264 0.4× 56 0.1× 175 0.4× 181 0.4× 47 2.2k
K Hirohata Japan 24 645 0.7× 98 0.1× 499 1.2× 75 0.2× 879 2.2× 91 2.1k

Countries citing papers authored by B L Hazleman

Since Specialization
Citations

This map shows the geographic impact of B L Hazleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B L Hazleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B L Hazleman more than expected).

Fields of papers citing papers by B L Hazleman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B L Hazleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B L Hazleman. The network helps show where B L Hazleman may publish in the future.

Co-authorship network of co-authors of B L Hazleman

This figure shows the co-authorship network connecting the top 25 collaborators of B L Hazleman. A scholar is included among the top collaborators of B L Hazleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B L Hazleman. B L Hazleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dasgupta, Bhaskar, Andrew Hutchings, J Hollywood, et al.. (2006). Clinical outcomes, quality of life and diagnostic uncertainty in the first year in polymyalgia rheumatica: A prospective cohort study. Investigative Radiology. 49(2). 116–23.
2.
Vollenhoven, Ronald van, Joy Schechtman, R Fleischmann, et al.. (2005). Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study. Queensland's institutional digital repository (The University of Queensland). 52(9). 12 indexed citations
3.
Isaacs, John D., AM Clarke-Cornwell, B L Hazleman, et al.. (2005). Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis. Arthritis Research. 7(Suppl 1). P46–P46. 8 indexed citations
4.
Isaacs, John D., AM Clarke-Cornwell, B L Hazleman, et al.. (2004). Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis. Oxford University Research Archive (ORA) (University of Oxford). 50. 1 indexed citations
5.
Speed, Cathy, et al.. (2002). Extracorporeal shock-wave therapy for tendonitis of the rotator cuff. Journal of Bone and Joint Surgery - British Volume. 84-B(4). 509–512. 26 indexed citations
6.
TeKoppele, J.M., et al.. (1999). Lysylhydroxylation and non-reducible crosslinking of human supraspinatus tendon collagen: changes with age and in chronic rotator cuff tendinitis. Annals of the Rheumatic Diseases. 58(1). 35–41. 106 indexed citations
7.
8.
Adebajo, Ade, P. Charles, R N Maini, & B L Hazleman. (1993). Autoantibodies in malaria, tuberculosis and hepatitis B in a West African population. Clinical & Experimental Immunology. 92(1). 73–76. 59 indexed citations
9.
Kyle, V, E. P. Wraight, & B L Hazleman. (1991). Liver scan abnormalities in polymyalgia rheumatica/giant cell arteritis. Clinical Rheumatology. 10(3). 294–297. 15 indexed citations
10.
Shipley, Michael, P A Bacon, H Berry, et al.. (1988). PULSED METHYLPREDNISOLONE IN ACTIVE EARLY RHEUMATOID DISEASE: A DOSE-RANGING STUDY. Lara D. Veeken. 27(3). 211–214. 18 indexed citations
11.
Chard, M D, J Calvin, Christopher P. Price, Tim E. Cawston, & B L Hazleman. (1988). Serum alpha 1 antichymotrypsin concentration as a marker of disease activity in rheumatoid arthritis.. Annals of the Rheumatic Diseases. 47(8). 665–671. 7 indexed citations
12.
Binder, Allan, et al.. (1985). Is therapeutic ultrasound effective in treating soft tissue lesions?. BMJ. 290(6467). 512–514. 130 indexed citations
13.
Kyle, V & B L Hazleman. (1985). Polymyalgia rheumatica/giant cell arteritis.. PubMed. 1(2). 171–81. 5 indexed citations
14.
Jones, Jeremy G., et al.. (1984). Abnormal radionuclide liver scans in giant cell arteritis.. Annals of the Rheumatic Diseases. 43(4). 583–585. 7 indexed citations
15.
Binder, Allan, et al.. (1983). A CLINICAL AND THERMOGRAPHIC STUDY OF LATERAL EPICONDYLITIS. Lara D. Veeken. 22(2). 77–81. 36 indexed citations
16.
Hazleman, B L. (1982). The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens.. Annals of the Rheumatic Diseases. 41. 12–17. 25 indexed citations
17.
Jones, Jeremy G. & B L Hazleman. (1981). Prognosis and management of polymyalgia rheumatica.. Annals of the Rheumatic Diseases. 40(1). 1–5. 190 indexed citations
18.
Jones, Jeremy, et al.. (1981). Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis. Annals of the Rheumatic Diseases. 40(5). 493–495. 45 indexed citations
19.
Mowat, A G, et al.. (1973). Post-operative wound healing in patients with rheumatoid arthritis.. Annals of the Rheumatic Diseases. 32(3). 273–274. 12 indexed citations
20.
Mason, Matthew, H. L. F. Currey, C. G. Barnes, et al.. (1969). Azathioprine in Rheumatoid Arthritis. BMJ. 1(5641). 420–422. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Trotta Breakdown of academic impact, for papers by Gurtej S. Cheema Breakdown of academic impact, for papers by Conny J. van der Laken Breakdown of academic impact, for papers by C Nagant de Deuxchaisnes Breakdown of academic impact, for papers by H. Roels Breakdown of academic impact, for papers by Philippe Dieudé Breakdown of academic impact, for papers by Christina Duftner Breakdown of academic impact, for papers by Peter Youssef Breakdown of academic impact, for papers by Alfred J. Fish Breakdown of academic impact, for papers by K Hirohata
Rankless by CCL
2026